Day: October 26, 2022

Zapol’skii, Viktor A.; Bilitewski, Ursula; Kupiec, Soeren R.; Ramming, Isabell; Kaufmann, Dieter E. published an article in 2020, the title of the article was Polyhalonitrobutadienes as versatile building blocks for the biotargeted synthesis of substituted N-heterocyclic compounds.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

Substituted nitrogen heterocycles are structural key units in many important pharmaceuticals. A new synthetic approach towards heterocyclic compounds displaying antibacterial activity against Staphylococcus aureus or cytotoxic activity has been developed. Selective synthesis of a series of 64 new N-heterocycles from the three nitrobutadienes, 2-nitroperchloro-1,3-butadiene, 4-bromotetrachloro-2-nitro-1,3-butadiene and (Z)-1,1,4-trichloro-2,4-dinitrobuta-1,3-diene, proved feasible. Their reactions of these butadienes with N-, O- and S-nucleophiles provided rapid access to push-pull substituted benzoxazolines, benzimidazolines, imidazolidines, thiazolidinones, pyrazoles, pyrimidines, pyridopyrimidines, benzoquinolines, isothiazoles, dihydroisoxazoles and thiophenes with unique substitution patterns. Antibacterial activities of the synthesized compounds were examined Seven studied compounds exhibited a significant cytotoxicity with IC50-values from 1.05 to 20.1μM. In conclusion, it was demonstrated that polyhalonitrobutadienes have an interesting potential as structural backbones for a variety of highly functionalized, pharmaceutically active heterocycles. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to butadiene nitro polyhalo preparation heterocyclization, nitrogen heterocycle preparation antitumor antibacterial activity, heterocyclization, medicinal chemistry, nitrogen heterocycles, nucleophilic substitution, polyhalonitrobutadienes and other aspects.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On July 25, 2022, Zhou, Jimei; Jia, Minxian; Song, Menghui; Huang, Zhiliang; Steiner, Alexander; An, Qidong; Ma, Jianwei; Guo, Zhiyin; Zhang, Qianqian; Sun, Huaming; Robertson, Craig; Bacsa, John; Xiao, Jianliang; Li, Chaoqun published an article.Related Products of 39512-49-7 The title of the article was Chemoselective Oxyfunctionalization of Functionalized Benzylic Compounds with a Manganese Catalyst. And the article contained the following:

Reported in this study is a new non-heme Mn catalyst stabilized by a bipiperidine-based tetradentate ligand, which enables methylene oxidation of benzylic compounds RCH2(CH2)nCH2R1 (R = Ph, 4-chlorophenyl, 2-bromophenyl, etc.; R1 = COOH, Me, Et, etc.) by H2O2, showing high activity and excellent chemoselectivity under mild conditions. The protocol tolerates an unprecedentedly wide range of functional groups, including carboxylic acid and derivatives, ketone, cyano, azide, acetate, sulfonate, alkyne, amino acid, and amine units, thus providing a low-cost, more sustainable and robust pathway for the facile synthesis of ketones RC(O)(CH2)nCH2R1, increase of complexity of organic mols., and late-stage modification of drugs. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Related Products of 39512-49-7

The Article related to aryl ketone preparation chemoselective green chem, heterocyclic preparation chemoselective green chem, aromatic hydrocarbon oxidation manganese catalyst, benzylic oxidation, cyclic imines, ketones, manganese catalysts, selective oxidation and other aspects.Related Products of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Zapol’skii, Viktor A.; Berneburg, Isabell; Bilitewski, Ursula; Dillenberger, Melissa; Becker, Katja; Jungwirth, Stefan; Shekhar, Aditya; Krueger, Bastian; Kaufmann, Dieter E. published an article in 2022, the title of the article was Chemistry of polyhalogenated nitrobutadienes, 17: efficient synthesis of persubstituted chloroquinolinyl-1H-pyrazoles and evaluation of their antimalarial, anti-SARS-CoV-2, antibacterial, and cytotoxic activities.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

A series of 26 novel 1-(7-chloroquinolin-4-yl)-4-nitro-1H-pyrazoles bearing a dichloromethyl and an amino or thio moiety at C3 and C5 has been prepared in yields up to 72% from the reaction of 1,1-bisazolyl-, 1-azolyl-1-amino-, and 1-thioperchloro-2-nitrobuta-1,3-dienes with 7-chloro-4-hydrazinylquinoline. A new way for the formation of a pyrazole cycle from 3-methyl-2-(2,3,3-trichloro-1-nitroallylidene)oxazolidine is also described. In addition, the antimalarial activity of the synthesized compounds has been evaluated in vitro against the protozoan malaria parasite Plasmodium falciparum. Notably, the I and 7-chloro-4-(3-((4-chlorophenyl)thio)-5-(dichloromethyl)-4-nitro-1H-pyrazol-1-yl)quinoline inhibited the growth of the chloroquine-sensitive Plasmodium falciparum strain 3D7 with EC50 values of 0.2 ± 0.1μM (85 ng/mL, 200 nM) and 0.2 ± 0.04μM (100 ng/mL, 200 nM), resp. Two compounds (I and II) have also been tested for anti-SARS-CoV-2, antibacterial, and cytotoxic activity. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to persubstituted chloroquinolinyl pyrazole preparation antimalarial antisars cov2 antibacterial cytotoxic, 1h-pyrazoles, 2-nitroperchlorobutadiene, anti-sars-cov-2 activity, antimalarial activity, chloroquine, nucleophilic vinylic substitution and other aspects.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Redzicka, Aleksandra; Czyznikowska, Zaneta; Wiatrak, Benita; Gebczak, Katarzyna; Kochel, Andrzej published an article in 2021, the title of the article was Design and synthesis of N-substituted 3,4-pyrroledicarboximides as potential anti-inflammatory agents.COA of Formula: C11H14ClNO And the article contains the following content:

The biol. activity of the newly designed and synthesized series N-substituted 3,4-pyrroledicarboximides I [R = Bu, Ph, 3-chlorophenyl; R1 = hydroxy; R2 = 1-hydroxyethyl, pyrimidin-2-yl, cyclohexyl etc.; X = C, N, O] was described. The compounds I were obtained in good yields by one-pot, three-component condensation of pyrrolo[3,4-c]pyrroles with secondary amines and an excess of formaldehyde solution in C2H5OH. The structural properties of the compounds I were characterized by 1H NMR, 13C NMR FT-IR, MS, and elemental anal. Moreover, single crystal X-ray diffraction has been recorded for compound I [R = 3-chlorophenyl; R2 = cyclohexyl; X = N]. The colorimetric inhibitor screening assay was used and obtained their potencies and inhibited COX-1 and COX-2 enzymes. According to the results, all of the tested compounds I inhibited the activity of COX-1 and COX-2. Theor. modeling was also applied to describes the binding properties of compoundsI towards COX-1 and COX-2 cyclooxygenase isoform. The data were supported by QSAR study. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).COA of Formula: C11H14ClNO

The Article related to aminomethylpyrrolopyrroledione preparation antiinflammatory docking cyclooxygenase inhibitor analgesic antioxidant, cox-1/cox-2 inhibition, mannich bases, analgesic activity, cyclic imides, docking study, inflammatory agents, pyrrolo[3,4-c]pyrrole and other aspects.COA of Formula: C11H14ClNO

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On October 1, 2013, Wang, Min; Gao, Mingzhang; Zheng, Qi-Huang published an article.Reference of 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was A high-yield route to synthesize the P-glycoprotein radioligand [11C]N-desmethyl-loperamide and its parent radioligand [11C]loperamide. And the article contained the following:

N-Desmethyl-loperamide and loperamide were synthesized from α,α-diphenyl-γ-butyrolactone and 4-(4-chlorophenyl)-4-hydroxypiperidine in five and four steps with 8% and 16% overall yield, resp. The amide precursor was synthesized from 4-bromo-2,2-diphenylbutyronitrile and 4-(4-chlorophenyl)-4-hydroxypiperidine in 2 steps with 21-57% overall yield. [11C]N-Desmethyl-loperamide and [11C]loperamide were prepared from their corresponding amide precursor and N-desmethyl-loperamide with [11C]CH3OTf through N-[11C]methylation and isolated by HPLC combined with solid-phase extraction (SPE) in 20-30% and 10-15% radiochem. yields, resp., based on [11C]CO2 and decay corrected to end of bombardment (EOB), with 370-740 GBq/μmol specific activity at EOB. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Reference of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to radioligand desmethylloperamide loperamide preparation, butyrolactone hydroxypiperidine ring opening, automation, brain imaging, p-glycoprotein (p-gp), positron emission tomography (pet), [(11)c]loperamide, [(11)c]n-desmethyl-loperamide ([(11)c]dlop) and other aspects.Reference of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On January 12, 2017, Bradner, James; Buckley, Dennis; Winter, Georg published a patent.Safety of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid The title of the patent was Preparation of bifunctional molecules for inducing targeted protein degradation. And the patent contained the following:

The title bifunctional compounds Degron-Linker-Targeting Ligand [Degron = I (ring A = II, III; Y = a bond, O, NH, etc.; X = C(O), C(R3); X1-X2 = C(R3):N or C(R3)2C(R3)2; R1 = halo, NO2, NH2, etc.; R3 = H, alkyl optionally substituted with aryl or 5-10 membered heteroaryl; each R31 = (independently) alkyl; R4 = (independently) H or alkyl; or two R4, together with the carbon atom to which they are attached, form C(O), carbocycle, or 4-6 membered heterocycle comprising 1-2 heteroatoms selected from N and O; R5 = H, alkyl, F or Cl; n = 0-2; m = 0-3; t = 0-1); Linker = IV (p1 = 0-12; p2 = 0-12; p3 = 0-6; each W = (independently) absent, CH2, O, S, NH or NR5; Z = absent, CH2, O, NH or NR5; each R5 = (independently) alkyl; Q = absent, C(O)NH, C(O)O, etc.); Targeting Ligand = V (ring containing T1-T5 = (a) T1, T2, T4 = N; T3, T5 = C, or (b) T1 = N, T2 = O; T3-T5 = C; A1 = S or C:C; A2 = NR15 or O; nn1 = 0-2; each R11 = (independently) alkyl, (CH2)0-3CN, (CH2)0-3halogen, etc.; R12 = H, alkyl, (CH2)0-3heterocyclyl, etc.; nn2 = 0-3; each R13 = alkyl, (CH2)0-3CN, (CH2)0-3halogen, etc.; R14 = alkyl; R15 = H or alkyl); with the proviso] which act as protein degradation inducing moieties, were prepared E.g., a multi-step synthesis of VI, starting from JQ1 (VII), was described. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the title bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. Exemplified compounds I demonstrated to have potent biol. activities, e.g., binding to the protein target (e.g. BRD4), mediating protein degradation, etc. (data given). The present application also provides methods for making compounds of the application and intermediates thereof. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).Safety of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid

The Article related to bifunctional compound preparation targeted protein degradation inducer cereblon binding, e3 ubiquitin ligase binding bifunctional compound preparation proliferative disorder, bromodomain brd4 protein degradation inducer bifunctional compound preparation and other aspects.Safety of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 21, 2006, Paone, Daniel V.; Nguyen, Diem N.; Shaw, Anthony W.; Burgey, Christopher S.; Tucker, Thomas J.; Graham, Samuel L. published a patent.Name: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Preparation of oxoimidazopyridylpiperidinylcarbonylaminopyridones and related compounds as calcitonin gene-related peptide (CGRP) receptor antagonists. And the patent contained the following:

Title compounds [I; Z = Q1, Q2; A = N, CR2; B = O, S; R1, R2, R7a, R7b = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2, R2R2 = atoms to form rings; R3 = H, F, cyano, CO2R4, (substituted) alkyl; W = O, NR4, C(R4)2; X = C, S; Y = O, (R4)2, NCN, NCONH2, O2; J = bond, C(R6)2, O, NR6; V = bond, C(R6)2, O, S, SO, SO2, NR6, etc.; GL = N, NC(R6)2, C:CR6, CN, CR6, etc.; Q = CR7a, C(R7a)2, CO, S, SO, SO2, N, NR7a; T = CR7b, C(R7b)2, CO, S, SO, SO2, N, NR7b; with provisos], were prepared for treatment of headache, migraine, and cluster headache. Thus, N-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (preparation given), phenylboronic acid, diisopropylamine, Pd(OAc)2, and 3,3′,3”-phosphinidynetris(benzenesulfonic acid) trisodium salt were heated in DMF/H2O at 80° for 18 h to give N-(1-methyl-2-oxo-5-phenyl-1,2-dihydropyridin-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide as the trifluoroacetate. I generally antagonized CGRP receptors with Ki or IC50 values of ≤50 μM. The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Name: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

The Article related to oxoimidazopyridylpiperidinylcarbonylaminopyridone preparation calcitonin gene related peptide antagonist, cgrp antagonist pyridone oxoimidazopyridyl piperidinyl carbamoyl preparation, piperidinecarboxamide oxopyridyl oxoimidazopyridyl preparation headache migraine treatment and other aspects.Name: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 19, 2022, Chen, Jia-Hao; Teng, Ming-Ya; Huang, Fan-Rui; Song, Hong; Wang, Zhen-Kai; Zhuang, He-Lin; Wu, Yong-Jie; Wu, Xu; Yao, Qi-Jun; Shi, Bing-Feng published an article.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Cobalt/Salox-Catalyzed Enantioselective Dehydrogenative C-H Alkoxylation and Amination. And the article contained the following:

Desymmetrization of diarylphosphinamides Ar2P(O)NHQ (Q = 8-quinolinyl) catalyzed by cobalt chiral Salox complexes (Salox = 2-(4-R-2-hydroxyphenyl)-4-phenyl-5-R1-oxazole) proceeds as dehydrogenative aromatic C-H alkoxylation and amination in one or both o-positions of one of the Ar rings. The past decade has witnessed a rapid progress in asym. C-H activation. However, the enantioselective C-H alkoxylation and amination with alcs. and free amines remains elusive. Herein, we disclose the first enantioselective dehydrogenative C-H alkoxylation and amination enabled by a simple cobalt/salicyloxazoline (Salox) catalysis. The use of cheap and readily available cobalt(II) salts as catalysts and Saloxs as chiral ligands provides an efficient method to access P-stereogenic compounds in excellent enantioselectivities (up to >99% ee). The practicality of this protocol is demonstrated by gram-scale preparation and further derivatizations of the resulting P-stereogenic phosphinamides, which offering a flexible asym. alternative to access P-stereogenic mono- and diphosphine chiral ligands. Preliminary mechanistic studies on the enantioselective C-H alkoxylation reaction suggest that a cobalt(III/IV/II) catalytic cycle might be involved. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to phosphinamide diaryl dehydrogenative alkoxylation amination desymmetrization cobalt salox catalyst, aromatic ch activation desymmetrization diarylphosphinamide alc amine cobalt catalyst, c−h alkoxylation, c−h amination, enantioselectivity, octahedral cobalt catalysis, salicyloxazoline and other aspects.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On May 31, 2017, Dalwadi, Dhwanil A.; Kim, Seongcheol; Schetz, John A. published an article.Name: 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia. And the article contained the following:

Glial cells play a critical role in neuronal support which includes the production and release of the neurotrophin brain-derived neurotrophic factor (BDNF). Activation of the sigma-1 receptor (S1R) has been shown to attenuate inflammatory stress-mediated brain injuries, and there is emerging evidence that this may involve a BDNF-dependent mechanism. In this report we studied S1R-mediated BDNF release from human astrocytic glial cells. Astrocytes express the S1R, which mediates BDNF release when stimulated with the prototypical S1R agonists 4-PPBP and (+)-SKF10047. This effect could be antagonized by a selective concentration of the S1R antagonist BD1063. Haloperidol is known to have high affinity interactions with the S1R, yet it was unable to facilitate BDNF release. Remarkably, however, two metabolites of haloperidol, haloperidol I and haloperidol II (reduced haloperidol), were discovered to facilitate BDNF secretion and this effect was antagonized by BD1063. Neither 4-PPBP, nor either of the haloperidol metabolites affected the level of BDNF mRNA as assessed by qPCR. These results demonstrate for the first time that haloperidol metabolites I and II facilitate the secretion of BDNF from astrocytes by acting as functionally selective S1R agonists. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Name: 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to human astroglia haloperidol metabolite brain neurotrophic factor sigma receptor, (+)-skf10047, 4-ppbp, astrocytes, bd1063, bdnf, haloperidol (pubchem cid: 3559), haloperidol metabolite i, haloperidol metabolite iii, in situ elisa, ne-100, neurotrophin, pf-04418948, pge2, reduced haloperidol, sigma receptor and other aspects.Name: 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On May 7, 2020, Hehn, Joerg P.; Blum, Andreas; Hucke, Oliver; Peters, Stefan published a patent.Recommanded Product: 1251006-64-0 The title of the patent was Preparation of pyridine-3-sulfonamide derivatives as amine oxidase copper containing 3 (AOC3) inhibitors and pharmaceutical compositions and uses thereof. And the patent contained the following:

The invention relates to new pyridinyl sulfonamide derivatives of the formula I [ring A = azetidin-1-yl, pyrrolidin-1-yl, 3-azabicyclo[3.1.0]hexan-3-yl, or piperidin-4-yl; R1 = H, F, Ci, Br, cyano, OH, or each (un)substituted C1-4-alkyl, C1-4-alkyloxy, (CH2)m-CO2H, (CH2)m-C(O)O-(C1-4-alkyl), (CH2)m-C(O)-heterocyclyl, (CH2)m-C(O)NH2, (CH2)m-C(O)NH-(C1-4-alkyl), (CH2)m-C(O)-N-(C1-4-alkyl)2, C(O)-NH-C3-6-cycloalkyl, C(O)-NH-heterocyclyl, (CH2)m-NH-C(O)(C1-3-alkyl), N-(C1-3-alkyl)-C(O)-(C1-4-alkyl), N-(C1-3-alkyl)-C(O)NH2, NH-C(O)NH-(C1-4-alkyl), heterocyclyl, or Ph; wherein multiple R1 may be identical or different, if n = 2; n = 1 or 2; m = 0, 1, or 2] or salts thereof. The compounds I or salts thereof are selective inhibitors of AOC3 (amine oxidase, copper containing 3; vascular adhesion protein 1) and are useful for the treatment of cancer, NASH (non-alc. steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy, or stroke. Thus, a solution of 0.19 mmol 1-[1-(6-chloropyridine-3-sulfonyl)piperidin-4-yl]-3-methylimidazolidin-2-one in NMP and Et3N was cooled in an ice bath, treated with a solution of 0.19 mmol tert-butyl-N-[2-(fluoromethylidene)-3-hydroxypropyl]carbamate in 0.5 mL THF and 390μL 2 M sodium tert-butoxide/THF, and stirred at room temperature for 2 h to give 1-[1-[6-((Z)-2-(tert-butoxycarbonylamino)methyl-3-fluoroallyloxy)pyridine-3-sulfonyl]piperidin-4-yl]-3-methylimidazolidin-2-one (isolated as trifluoroacetate salt) which was stirred with CF3CO2H in CH2Cl2 at room temperature for 2 h to give 1-[1-[6-((Z)-2-aminomethyl-3-fluoroallyloxy)pyridine-3-sulfonyl]piperidin-4-yl]-3-methylimidazolidin-2-one trifluoroacetate (II). II showed IC50 of 7, 120, 15,265 nM, and >50.0μM against AOC3, AOC2, AOC1, and monoamine oxidase-A (MAO-A), resp. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Recommanded Product: 1251006-64-0

The Article related to pyridinesulfonamide preparation aoc3 inhibitor, amine oxidase copper containing 3 aoc3 inhibitor, vascular adhesion protein 1 inhibitor, azetidinylsulfonylpyridine pyrrolidinylsulfonylpyridine preparation aoc3 inhibitor, azabicyclohexanylsulfonylpyridine piperidinylsulfonylpyridine preparation aoc3 inhibitor and other aspects.Recommanded Product: 1251006-64-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem